Evaluating mismatch repair deficiency for solid tumor immunotherapy eligibility: immunohistochemistry versus microsatellite molecular testing

Omer A M Saeed,Steven A Mann,Claudio Luchini,Kun Huang,Shaobo Zhang,Joyashree D Sen,Maria L Piredda,Mingsheng Wang,Lee Ann Baldrige,R Matthew Sperling,Kendra L Curless,Liang Cheng,Omer A.M. Saeed,Steven A. Mann,Joyashree D. Sen,Maria L. Piredda,R. Matthew Sperling,Kendra L. Curless
DOI: https://doi.org/10.1016/j.humpath.2021.05.009
IF: 3.526
2021-09-01
Human Pathology
Abstract:<p>While many landmark solid tumor immunotherapy studies show clinical benefits for solid tumors with high microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR), the methodologies focus only on confirmatory polymerase chain reaction (PCR) testing for MSI-H. Since some tumors are either dMMR or MSI-H but not the other, clinicians must choose between two testing methods for a broad patient population. We investigated the level of correlation between MMR protein immunohistochemistry (IHC) and microsatellite PCR testing results in 62 cancer patients. Thirty-five of the 62 cases (56.5%) were MSI-H by PCR, whereas 35 (56.5%) were dMMR by IHC. MMR IHC results correlated well with MSI PCR in 32 co-positive cases (91.4%) and 24 co-negative cases (88.9%). Six discrepant cases (9.7%) were identified, among which three were MSI-H and MMR intact, and three were dMMR and microsatellite stable. The results of this study highlight the implications of dMMR/MSI testing strategies on precision oncology. Co-testing with both MMR IHC and MSI PCR may be an effective screening strategy for evaluating immunotherapy eligibility status for solid tumors.</p>
pathology
What problem does this paper attempt to address?